Evidence map›Paper›PMID 39006195›Full record

ArticleInternational journal of molecular and cellular medicine2023

Effect of

Tahmine Ostovar, Sahar Rezaei, Hajar Shokri-Afra, Sadra Samavarchi Tehrani, Fatemeh Namvarjah, Masoume Aliabadi, Hosein Effatpanah, Hemen Moradi-Sardareh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular and cellular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tahmine OstovarInternational Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Sahar RezaeiDepartment of Clinical Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Hajar Shokri-AfraGut and Liver Research Center, Non-communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Sadra Samavarchi TehraniEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Science, Tehran, Iran.
Fatemeh NamvarjahDepartment of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Masoume AliabadiDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hosein EffatpanahDepartment of Public Health, Asadabad School of Medical Sciences, Asadabad, Iran.
Hemen Moradi-SardarehAsadabad School of Medical Science, Asadabad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF) is a lethal inflammatory disease and there has been no effective medication for this progressive disease up to now. Paraquat is commonly used in agricultural settings to control weed growth and is one of the important risk factors for PF. Additionally, emerging evidence has demonstrated

Indexed as

HydroxyprolinemalondialdehydeParaquatPulmonary fibrosis

Identifiers

PMID39006195
PMCPMC11240055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.